Abstract
Prevention of mother to child transmission (PMTCT) of Human Immunodeficiency virus (HIV) during pregnancy is one of the great successes over the last two decades. Various regimens have been tried, eventually leading to the achievement of very low rates of PMTCT of HIV. The ultimate aim is to eliminate the mother to child transmission (EMTCT) of HIV. EMTCT includes the period from preconception to 18 months of age or 6 weeks post-cessation of breastfeeding if continued beyond18 months. The number of HIV exposed uninfected (HEU) infants exposed to HIV and antiretrovirals is utero and during breastfeeding is increasing. The care of the newborn of an HIV positive mother should not end at birth. A continuum of care extending postpartum and postnatally is required to identify and prevent infections. Neonates born to HIV positive mothers are exposed in-utero to antiretroviral drugs, antibiotics, anti-tuberculous therapy etc. which may lead to altered fetal programming. Antiretroviral drugs have the potential of causing adverse effects in the newborn. One needs to have a high index of suspicion when examining an HIV exposed neonate. Investigations must be done timeously to prevent further complications and long-term follow up is required for some of the neonates.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
UNAIDS. WHO global AIDS update. Ending AIDS towards the 90–90-90 targets. UNAIDS: Geneva; 2017.
The Working Group on Mother-To-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(5):506–10.
Tess BH, Rodrigues LC, Newell ML, Dunn DT, Lago TDG. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in São Paulo state. Brazil. AIDS. 1998;12:513–20.
Baggaley R, Doherty M, Ball A, Ford N, Gottfried HG. Department of HIV/ AIDS, World Health Organization, Geneva, Switzerland. The strategic use of Antiretrovirals to prevent HIV infection: a converging agenda. Clin Infect Dis. 2015;60(Suppl 3):159–60.
French CE, Thorne C, Byrne L, Cortina-Borja M, Tookey PA. Presentation for care and antenatal management of HIV in the UK, 2009-2014. HIV Med. 2017;18(Suppl 3):161–704.
Kourtis AP, Bullerys M, Nesheim S, et al. Understanding the timing of transmission from mother to child. JAMA. 2001;285(6):709–12.
Connor EM, Sperling RS, Gilber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trial group protocol 076 study group. NEJM. 1994;331:1173–80.
Copper ER, Charurat M, Mofenson L, Women and infants Transmission Study Group, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–94.
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Rockville: AIDSinfo; 2010. p. 1–17.
Fawzi W, Msamanga G, Renjifo B, et al. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS. 2001;15:1157–65.
Neveu D, Viljoen J, Bland RM, et al. Cumulative exposure to cell-free HIV in breast milk, rather than feeding pattern per se, identifies postnatally infected infants. Clin Infect Dis. 2011;52:819–25.
Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis. 2003;187:741–7.
Gaur A, Dorminguez KL, Kalish ML, et al. Practice of feeding premasticated food to infants: a potential risk factor for HIV transmission. Pediatrics. 2009;124:658–66.
Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Rev Med Virol. 2007;17:381–403.
Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis. 2006;6:726–32.
Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695–705.
Short CE, Douglas M, Smith JH, Taylor GP. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med. 2014;15:233–8.
Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18:2337–9.
Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIVinfected women in the United Kingdom and Ireland. AIDS. 2007;21:1019–26.
Ekouevi DK, Coffie P, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d’Ivoire. AIDS. 2008;22:1815–20.
Li N, Sando MM, Spiegelman D, et al. Antiretroviral therapy in relation to birth ART among HIV-infected women: a cohort study. J Infect Dis. 2016;213:1057–64.
Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;364:1863–70.
Zash R, Souda S, Chen JY, et al. Reassuring birth outcomes with tenofovir/ emtricitabine/ efavirenz used for prevention of mother to child transmission of HIV in Botswana. J Acquir Immune Defic Syndr. 2016;71:428–36.
Malaba TR, Phillips T, Le Roux S, Brittain K, Zerbe A, Petro G, Ronan A, McIntyre JA, Abramsand EJ, Myer L. Antiretroviral therapy use during pregnancy and adverse birth outcomes in South African women. Int J Epidemiol. 2017;46:1678–89.
CHEN JY, Boer K, Nellen JF, Patel D, et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG. 2007;114:148–55.
Olagbuji BN, Ezeanochie MC, Ande AB, Oboro VO. Obstetric and perinatal outcome in HIV positive women receiving HAART in urban Nigeria. Arch Gynecol Obstet. 2010;281:991–4.
le Roux SM, Jao J, Brittain K, Philips TK, Olatunbosun S, Ronan A, et al. Tenofovir exposure in utero and linear growth in HIV exposed, uninfected infants. AIDS. 2017;31:97–103.
Obumneme-Anyim I, Ibeziako N, Emodi I, Ikefuna A, Oguonu T. Hematological indices at birth of infants of HIV-positive mothers participating in a prevention of mother-to-child transmission program. J Trop Pediatr. 2016;62(Suppl 1):3–9.
Jauniaux E, Nessmann C, Imbert MC, et al. Morphological aspects of the placenta in HIV pregnancies. Placenta. 1988;9:633–42.
Vermaak A, Theron GB, Schubert PT, et al. Morphologic changes in the placentas of HIV-positive women and their association with degree of immune suppression. Int J Gynaecol Obstet. 2012;119:239–43.
Schwartz DA, Sungkarat S, Shaffer N, et al. Placental abnormalities associated with human immunodeficiency virus type 1 infection and perinatal transmission in Bangkok, Thailand. J Infect Dis. 2000;182:1652–7.
Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112–5.
Noguera A, Fortuny C, Muñoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to Antiretrovirals. Pediatrics. 2004;114:e598–603.
Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084–9.
Barret B, Tardieu M, Rustin P, French Perinatal Cohort Study Group, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS. 2003;17:1769–85.
Jao J, Abrams EJ. Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants. Pediatr Infect Dis J. 2014;33(7):734–40.
Phiri K, Hernandez-Diaz S, Dugan KB, Williams PL, Dudley JA, Jules A, et al. First trimester exposure to antiretroviral therapy and risk of birth defect. Pediatr Infect Dis J. 2014;33(7):741–6.
Prieto LM, González-Tomé MI, Muñoz E, et al. Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009. BMC Infect Dis. 2014;14:700.
Sibiude J, Mandelbrot L, Blanche S, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11(4):e100163.
Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. Morb Mortal Wkly Rep. 2008;57(1):1–5.
Watts D, Li D, Handelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the women and infants transmission study. J Acquir Immune Defic Syndr. 2007;44(3):299–30.
Brogly SB, Abzug MJ, Watts DH, et al. Birth defects among children born to HIV-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J. 2010;29(8):721–7. https://doi.org/10.1097/INF.0b013e3181e74a2f.
Adachi K, Xu J, Yeganeh N, Camarca M, Morgado MG, Watts H, Mofenson LM, et al. Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission for the NICHD HPTN 040 Study Team. PLoS One. 2018;13(1):e0189851. https://doi.org/10.1371/journal.pone.0189851.
World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections – 2008. Geneva: World Health Organization; 2012.
McClelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS. 2001;15(1):105±10.
Wabwire-Mangen F, Gray RH, Mmiro FA, Ndugwa C, Abramowsky C, Wabinga H, et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr. 1999;22(4):379±85.
Rotchford K, Strum AW, Wilkinson D. Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis. 2000;27(5):243±8.
Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis. 2008;35(11):946±59. https://doi.org/10.1097/OLQ.0b013e3181812d15.
Chen KT, Segu M, Lumey LH, Kuhn L, Carter RJ, Bulterys M, et al. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstetr Gynaecol. 2005;106(6):1341±8. https://doi.org/10.1097/01.AOG.0000185917.90004.7c.
Drake AL, John-Stewart GC, Wald A, Mbori-Ngacha DA, Bosire R, Wamalwa DC, et al. Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstetr Gynecol. 2007;109(2 Pt 1):403±9. https://doi.org/10.1097/01.AOG.000025151.27725.5c.
Lurain NS, Robert ES, Xu J, Camarca M, Landay A, Kovacs AA, et al. HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis. 2004;190(3):619±23. https://doi.org/10.1086/422533.
Adachi K, Xu J, Ank B, Watts DH, Mofenson LM, Pilotto JH, et al. Cytomegalovirus urinary shedding in HIV-infected pregnant women and congenital cytomegalovirus infection. Clin Infect Dis. 2017;65:405–13. https://doi.org/10.1093/cid/cix222.
Kovacs A, Schluchter M, Easley K, et al. Pediatric pulmonary and cardiovascular complications of vertically transmitted HIV infection study group. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. N Engl J Med. 1999;341:77–84.
Day JH, Grant AD, Fielding KL, et al. Does tuberculosis increase HIV load? J Infect Dis. 2004;190:1677–84.
Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996;157:1271–8.
Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest. 1995;95:2324–31.
Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001;123:233–8.
Pillay T, Adhikari M, Coovadia HM, Moodley J, Khan M, Sullivan JL. In utero HIV infection in pregnancies complicated by tuberculosis in Durban, South Africa. Arch Dis Child Fetal Neonatal Ed. 2004;89:F468–9.
Gupta A, Bhosale R, Kinikar A, et al. Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. J Infect Dis. 2011;203:358–62.
Tess BH, Rodrigues LC, Newell ML, Dunn DT, Lago TD. Infant feeding and risk of mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. Sao Paulo Collaborative Study for Vertical Transmission of HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:189–94.
Embree JE, Njenga S, Datta P, et al. Risk factors for postnatal mother-child transmission of HIV-1. AIDS. 2000;14:2535–41.
Lunney Kevin M, Iliff P, Mutasa K, et al. Associations between breast milk viral load, mastitis, exclusive breast-feeding, and postnatal transmission of HIV. Clin Infect Dis. 2010;50:762–9.
Slogrove AL, Goetghebuer T, Cotton MF, Singer J, Bettinger JA. Pattern of infectious morbidity in HIV exposed uninfected infants and children. Front Immunol. 2016;7:164. https://doi.org/10.3389/fimmu.2016.00164.
Dangor Z, Lala SG, Cutland CL, Koen A, Jose L, Nakwa F, et al. Burden of invasive Group B Streptococcus disease and early neurological sequelae in south African infants. PLoS One. 2015;10(4):e0123014. https://doi.org/10.1371/journal.pone.0123014.
Taron-Brocard C, Le Chenadec J, Faye A, Dollfus C, Goetghebuer T, Gajdos V, et al. Increased risk of serious bacterial infections due to maternal immuno-suppression in HIV-exposed uninfected infants in a European country. Clin Infect Dis. 2014;59(9):1332–45. https://doi.org/10.1093/cid/ciu586.
Epalza C, Goetghebuer T, Hainaut M, Prayez F, Barlow P, Dediste A, et al. High incidence of invasive Group B streptococcal infections in HIV-exposed uninfected infants. Pediatrics. 2010;126(3):e631–8. https://doi.org/10.1542/peds.2010-0183.
Cutland CL, Schrag SJ, Thigpen MC, Velaphi SC, Wadula J, Adrian PV, et al. Increased risk for Group B Streptococcus sepsis in young infants exposed to HIV, Soweto, South Africa, 2004–2008. Emerg Infect Dis. 2015;21(4):638. https://doi.org/10.3201/eid2104.141562.
Dauby N, Chamekh M, Melin P, Slogrove AL, Goetghebuer T. Increased risk of Group B Streptococcus invasive infection in HIV-exposed but uninfected infants: a review of the evidence and possible mechanisms. Front Immunol. 2016;7:505. https://doi.org/10.3389/fimmu.2016.00505.
World Health Organization. Hepatitis B factsheet. Geneva: WHO; 2017.
Andersson MI, Maponga TG, Ijaz S, Theron G, Preiser W, Tedder RS. High HBV viral loads in HIV-infected pregnant women at a tertiary hospital, South Africa. J Acquir Immune Defic Syndr. 2012;60(4):e111–2.
Tovo PA, Palomba E, Ferraris G, Principi N, Ruga E, Dallacasa P, et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Infect Dis. 1997;25(5):1121–4.
Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105:94–8.
Andersson MI, Rajbhandari R, Kew MC, Vento S, Preiser W, Hoepelman AIM, et al. Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. Lancet Glob Health. 2015;3:e358–e35.
Society for Maternal-Fetal Medicine (SMFM), Dionne-Odom J, Tita AT, Silverman NS. Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214(1):6–14. https://doi.org/10.1016/j.ajog.2015.09.100.
Koyanagi A, Humphrey JH, Ntozini R, et al. Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. Pediatr Infect Dis J. 2011;30:45–51.
de Moraes-Pinto MI, Verhoeff F, Chimsuku L, et al. Placental antibody transfer: influence of maternal HIV infection and placental malaria. Arch Dis Child Fetal Neonatal Ed. 1998;79:F202–F5.
de Moraes Pinto MI, Almeida ACM, Kenj G, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis. 1996;173:1077–84.
Cumberland P, Shulman CE, Maple PA, et al. Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis. 2007;196:550–7.
Afran L, Garcia Knight M, Nduati E, et al. HIV-exposed uninfected children: a growing population with a vulnerable immune system? Clin Exp Immunol. 2014;176:11–22.
Dauby N, Goetghebuer T, Kollmann TR, et al. Uninfected but not unaffected chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect Dis. 2012;12:330–40.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Singh, R. (2020). Care and Management of a Neonate Born to an HIV Positive Mother. In: Bobat, R. (eds) HIV Infection in Children and Adolescents. Springer, Cham. https://doi.org/10.1007/978-3-030-35433-6_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-35433-6_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35432-9
Online ISBN: 978-3-030-35433-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)